Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RN
Atrium Therapeutics, Inc. Common Stock
RNA
Mkt Cap
$131.5M
Volume
170.46K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RN
RNA
RN
Atrium Therapeutics, Inc. Common Stock
RNA
News
·
Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights
Mkt Cap
$133.8M
Volume
170.46K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the transactions.
GlobeNewswire Inc. · Jan 31, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO
Monteverde & Associates PC, a class action securities firm, is investigating four proposed mergers: The Brand House Collective's sale to Bed Bath & Beyond, Avidity Biosciences' acquisition by Novartis for $72 per share, NorthWestern Energy Group's sale to Black Hills Corp, and Two Harbors Investment Corp's merger with UWM Holdings Corporation. The firm is seeking shareholders with concerns about these transactions ahead of upcoming shareholder votes.
Benzinga · Jan 31, 2026
Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involving mergers and acquisitions.
GlobeNewswire Inc. · Nov 22, 2025
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Novartis anticipates 5-6% annual sales growth from 2025-2030, raised peak sales projections for key drugs like Kisqali and Scemblix, and expects to maintain operating margins above 40% while planning significant U.S. infrastructure expansion.
Benzinga · Nov 20, 2025
Novartis Maintains Outlook Even As Generics Bite Into Profits
Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.
Benzinga · Oct 28, 2025
Why Dyne Therapeutics Stock Crushed the Market on Monday
Dyne Therapeutics stock surged over 41% after Novartis announced a $12 billion acquisition of Avidity Biosciences, a peer biotech company developing similar muscle disorder therapies using antibody-based treatments.
The Motley Fool · Oct 27, 2025
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
Novartis will acquire Avidity Biosciences for $12 billion, focusing on its neuroscience pipeline and RNA-targeting platform, with shareholders receiving $72 per share and early-stage cardiology programs being spun off into a separate public company.
Benzinga · Oct 27, 2025
Stock Market Today: Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street—Novartis, Nucor, Waste Management In Focus
U.S. stock futures rose ahead of a busy week with earnings reports from major tech companies and the Federal Reserve's interest rate decision. Key events include earnings from Microsoft, Alphabet, Meta, Apple, and Amazon, with potential market-moving implications.
Benzinga · Oct 27, 2025
RNA STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF AVIDITY BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS
Law firm investigating the sale of Avidity Biosciences to Novartis at $72.00 per share, questioning whether the transaction fairly represents shareholder interests.
GlobeNewswire Inc. · Oct 26, 2025
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
Novartis announced plans to acquire Avidity Biosciences for $12 billion, strengthening its neuroscience pipeline with innovative RNA therapeutics targeting genetic neuromuscular diseases.
GlobeNewswire Inc. · Oct 26, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
RN
RNA
Atrium Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
RNA
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any RNA yet.
Related Tickers
Earnings